OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
AKI Staging (KDIGO)Anion Gap + Delta-DeltaCKD Stage (KDIGO)Creatinine ClearanceElectrolyte & Free WaterFENaFEUreaKFRE — Kidney Failure RiskKt/V DialysisSodium CorrectionUACRUPCRUrea Reduction RatioUric Acid & FEUAUrinary Anion GapWinter's FormulaeGFR (CKD-EPI)

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • AKI differential (Prerenal vs. ATN) in patients who have received loop or thiazide diuretics within 24 hours.
  • Cases where FENa is unreliable: diuretics, contrast nephropathy, pigment nephropathy, early ATN.
  • Non-oliguric AKI where FENa accuracy is reduced.
  • Suspicion of Hepatorenal Syndrome (HRS) — FEUrea is typically very low.

Key Advantage Over FENa

Diuretics block Na reabsorption in the loop of Henle, falsely elevating FENa above 1% even in pure prerenal states. Urea reabsorption is not affected by diuretics, making FEUrea a more reliable marker when diuretic therapy is active.

CLINICAL INSIGHT

How it Works

Formula

Interpretation Thresholds

< 35%
35–50%
> 50%

Physiological Rationale

In hypovolaemic states, the kidney maximally reabsorbs water and urea in the collecting duct under ADH stimulation, minimising urinary urea loss. In ATN, tubular cell damage impairs this reabsorption regardless of volume status, leading to high fractional excretion of urea in the urine.

CLINICAL INSIGHT

Practical Pearls

Accuracy Compared to FENa

  • FEUrea has sensitivity 86%, specificity 98% for prerenal AKI in patients on diuretics (Carvounis 2002).
  • Significantly superior to FENa in this population — FENa has only 48% sensitivity under diuretic use.
  • Most clinical guidelines recommend FEUrea as the first-line test if diuretics have been given.

Limitations

  • Less studied than FENa in non-diuretic settings.
  • Can be unreliable in patients with significant protein catabolism (urea generation affected).
  • Protein intake and muscle breakdown directly affect urea generation rates.
CLINICAL INSIGHT

Next Steps

Action Plan — Prerenal (< 35%)

  • Assess fluid status and administer cautious IV fluid challenge (250 mL bolus).
  • Review and hold nephrotoxins: NSAIDs, ACEi/ARBs, aminoglycosides.
  • Identify and treat the underlying cause: sepsis, dehydration, haemorrhage, cardiorenal syndrome.
  • Reassess creatinine and urine output in 4–6 hours after fluid resuscitation.

Action Plan — ATN (> 50%)

  • Stop aggressive IV fluid boluses — risk of fluid overload without renal recovery benefit.
  • Monitor for and treat AKI complications: hyperkalemia, metabolic acidosis, fluid overload.
  • Review recent nephrotoxin exposures (aminoglycosides, vancomycin, contrast, NSAIDs).
  • Nephrology consult if Stage 2–3 AKI or meeting RRT criteria.

Complementary Tools

CLINICAL INSIGHT

Evidence Base

Primary Reference

Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure.

Carvounis CP, Nisar S, Guro-Razuman S.Kidney Int.2002
CLINICAL INSIGHT

Background

Historical Context

FEUrea was proposed as a clinical tool in the early 2000s as a direct response to the recognised limitation of FENa in the modern era of widespread diuretic use. The landmark Carvounis study in 2002 finally provided the evidence base to make FEUrea a clinically actionable bedside calculation.

FEUrea

Fractional Excretion of Urea (FEUrea): Preferred over FENa when diuretics have been given — urea handling is not affected by loop diuretics, making it more reliable in this setting.

Plasma Values

Urine Values

No clinical reference data available.